Fresh analysis suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.
Research printed in a prominent health publication points out that while obese individuals often shed substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month after stopping.
"Users buying such drugs should be cognizant of the potential of rapid weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to original mass within about a year and a half.
Weighing Treatments
The study, which examined dozens of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone typically experience a more gradual weight regain—around 100 grams monthly—post-intervention.
Explaining the Rapid Regain
Experts suggest the way of the drugs accounts for the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than normal might result in the system to produce less of its own natural hormone, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication leads to hunger is uncontrolled, making overeating much more probable."
An Ongoing Issue?
Medical guidelines advise the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of weight regain, the therapy is often long-term.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes.
Patient Testimonies
Individuals who have discontinued the jabs explain a powerful resurgence of hunger.
"It felt as if a switch activating and I was suddenly extremely hungry," recalled one woman.
This difficulty is worsened if patients have not developed lasting dietary or behavioural modifications during treatment.
Widespread Use
Survey data indicate that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is greater among females compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while these medications are effective tools for weight loss, they are not a permanent solution and lasting health benefits relies on combined lifestyle changes.
